Articles by Sara Calabro - Pharmaceutical Executive

ADVERTISEMENT

Articles by Sara Calabro

King Without the Crown

While most of pharma tries to convince the world that R&D is the number-one priority, one specialty company boasts that it has no lab.
Jun 1, 2006

Under King's old strategy, there was no link between business opportunity and R&D. Today, the company only goes after drugs that meet the criteria of its targeted approach to acquisition.

Genzyme: The Price of Success

Genzyme put patients first, and grew to become a multi-billion-dollar company. But empires don't survive on altruism.
Mar 1, 2006

Genzyme has an impressive international record in regions with intact healthcare systems. but so far, algeria is one of very few countries where genzyme's drugs have gone from free to paid for. the company is basing a huge investment on faith.

Valeant Pharmaceuticals is Soldiering On

Nov 1, 2005

Valeant is banking on Viramidine, a pro-drug of its longtime cash cow, ribavirin, to catapult the company to the next level.

ADVERTISEMENT

Click here